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To the editor: 
The development of chronic obstructive pulmonary disease (COPD) is known to be 
influenced by both genetic and environmental factors (1, 2). Although smoking is generally 
considered the main environmental risk factor, only 25% of smokers develop COPD (3) while 
25–40% of COPD patients have never smoked (4). This indicates that there are large 
differences in individual susceptibility that may be at least partially attributable to genetic 
factors. Genome-wide association studies have identified several common genetic variants 
(minor allele frequency (MAF) >5%) that affect COPD susceptibility, but these only explain a 
small amount of individual risk to develop COPD (1). Rare genetic variants (MAF <1%) have 
largely been ignored, since genome wide association studies require huge sample sizes to 
reach statistical significance for rare variants because of their low allele frequencies in the 
general population. Rare genetic variants, similar to common variants, may affect COPD 
either through interaction with or independent of environmental factors such as smoking. In 
this study we aimed to identify rare genetic variants for COPD independent of 
environmental factors. 
We selected 36 unrelated subjects with airflow obstruction from the general-
population based Lifelines cohort study using the following criteria: FEV1/FVC <70%, 
FEV1/FVC <lower limit of normal, never smoked, no environmental smoking, and no 
occupational exposures to vapors, gases, dust, fumes, and pesticides. We performed whole 
genome sequencing (WGS) and prioritized predicted pathogenic sequencing variants in 
exomes using an in-house developed algorithm GAVIN (5). In general, variants present in 
more than five subjects appeared to be (alignment) artifacts, such as single nucleotide 
stretches or repeats. Therefore we only included variants that were carried by one to five 
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subjects. We found 7,355 predicted pathogenic rare variants of which 6,395 variants were 
carried by only one subject (Figure 1). Of interest, 122 rare genetic variants were carried by 
4 or 5 subjects and can actually be considered as common variants in our homogenous 
identification cohort based on their MAF >5%. 
We verified the relevance of these 122 rare variants in COPD in the general 
population by taking advantage of the imputed data of the UK Biobank. Here, imputed 
variants with an info-score below 0.5 and genotype values between 0.1 – 0.9 and 1.1 – 1.9 
were excluded. Overall, 42 of the 122 variants were imputed. Based on airflow obstruction 
defined as FEV1/FVC <70%, participants with imputed genotype data available were divided 
into cases (n=68,344) and controls (n=374,713). To assess if the frequencies of the 42 
imputed rare genetic variants were different between cases and controls, χ2 tests were 
performed and a Benjamini-Hochberg adjusted p-value below 25% was considered 
significant. A total of 7 rare variants present in the genes SERPINA1, CMYA5, OPA3, 
SUZ12P1, LRP5, KIF27 and TMC4 were more frequent in individuals with airflow obstruction. 
While we expected to find only rare variants with large effect sizes, the UK Biobank 
verification results found effect sizes for rare variants that are, remarkably, not very 
different from the effect sizes observed for common variants. This further reinforces the 
idea that very large sample sizes are required for the identification of rare variants in 
association studies.
By using a fixed effect meta-analysis, we subsequently studied 6 of the 7 variants 
(the variant in SUZ12P1 was not imputed) in two smaller general population-based cohorts: 
Lifelines and the Rotterdam Study. In here, airflow obstruction was defined as FEV1/FVC 
<70% and a meta-analysis p-value below 0.05 was considered significant. We replicated the 
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three variants present in Kinesin Family Member 27 (KIF27; Chr9:86495276), LDL Receptor 
Related Protein 5 (LRP5; Chr11:68174189)  and Outer Mitochondrial Membrane Lipid 
Metabolism Regulator (OPA3; Chr19:46088060) (Figure 2).  
None of the genes in which the new risk variants are located have been associated 
with respiratory diseases before. However, based on expression data available within the 
Genotype-Tissue Expression (GTEx) project, a comprehensive public resource to study 
tissue-specific gene expression, all three genes are expressed in lung tissue. KIF27 belongs to 
the kinesin superfamily of microtubule-based motors. This superfamily plays essential roles 
in cell division, cell motility, intracellular trafficking, control of microtubule dynamics, and 
ciliary function (6). OPA3 has been described as a protein involved in the mitochondrial 
fission machinery in cells and appears to be well conserved between different cell types (7). 
LRP5 is an essential component of the Wnt/β-catenin signalling pathway and known to be 
important for tissue development and homeostasis. Since all three genes are involved in 
processes important for the lung, it is highly interesting to further characterize the 
functional contribution of these variants in COPD.
Although studies on rare genetic variants are currently limited, we are not the first 
group that endeavored to identify and interpret rare genetic variants associated with COPD. 
However, compared to initiatives such as targeted re-sequencing and family-based studies 
(8, 9), our analysis strategy differs in three noteworthy ways: (1) it uses an untargeted, 
exome-wide approach, (2) it is independent of exposure to cigarette smoke, and (3) our 
results are applicable to general population cohorts. Nevertheless, we have to acknowledge 
limitations of our approach. First, we only selected rare genetic variants with a potential 
pathogenic risk and variants that are not detected by in silico prediction tools such as GAVIN 
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are neglected with our approach. Second, we used imputed data to identify rare genetic 
variants in the general population. Next to the fact that imputed data is an approximation of 
the genotype, not all the rare variants could be imputed in all datasets. Finally, the lack of 
replication of many variants may also be the result of our strategy to replicate only the exact 
variant in each population. Allele frequencies of rare variants tend to differ between 
populations and it may be interesting to see whether other variants in the same gene, or a 
cumulative gene-based risk score, are associated with airflow obstruction.  
In conclusion, our novel approach seems promising for exome-wide identification of 
rare genetic variants and novel candidate genes for COPD that arise independent of 
exposure to cigarette smoke in the general population. 
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FIGURE LEGENDS
Figure 1: Study flowchart. Whole-genome sequencing generated 747 million reads per 
sample on average, yielding an average coverage of 47x per base. Sequence variants were 
annotated for potential pathogenicity based on gene-specific CADD score thresholds and 
minor allele frequencies using GAVIN. Alignment artifacts such as single nucleotide stretches 
or repeats and variants located in mitochondrial DNA, X or Y chromosome were excluded. 
Distribution of the selected rare variants annotated as (likely) pathogenic among the 36 
subjects was assessed. Genetic variants carried by four or five subjects were imputed in UK 
Biobank (combined Haplotype Reference Consortium and UK10K haplotype resource 
reference panel) and differences in frequency of the imputed rare genetic variants between 
cases (FEV1/FVC <70%) and controls (FEV1/FVC >70%) were tested using a χ2 test. By using a 
fixed-effect meta-analysis, significant variants were replicated in Lifelines (Genome of the 
Netherlands reference panel) and the Rotterdam Study (Haplotype Reference Consortium 
reference panel). FEV1: Forced Expiratory Volume in one second; FVC: Forced Vital Capacity; 
MAF: Minor Allele Frequency; FDR: False Discovery Rate   
Figure 2: Odds ratios of variants that were significantly different between subjects with 
airflow obstruction and controls in the UK Biobank and meta-analysis of Lifelines and the 
Rotterdam Study. Odds ratios are presented with confidence intervals. ∞ indicates that no 
odds ratio could be calculated because this variant was not present in controls.
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